1. Home
  2. PHIN vs STOK Comparison

PHIN vs STOK Comparison

Compare PHIN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PHINIA Inc.

PHIN

PHINIA Inc.

HOLD

Current Price

$64.07

Market Cap

2.9B

Sector

N/A

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$33.95

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHIN
STOK
Founded
2023
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.0B
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
PHIN
STOK
Price
$64.07
$33.95
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$66.33
$36.10
AVG Volume (30 Days)
424.4K
702.1K
Earning Date
05-15-2026
04-15-2026
Dividend Yield
1.90%
N/A
EPS Growth
84.09
30.67
EPS
3.24
0.85
Revenue
N/A
$36,555,000.00
Revenue This Year
$6.60
$428.68
Revenue Next Year
$1.48
N/A
P/E Ratio
$19.48
$39.05
Revenue Growth
N/A
316.34
52 Week Low
$36.25
$5.35
52 Week High
$81.00
$40.22

Technical Indicators

Market Signals
Indicator
PHIN
STOK
Relative Strength Index (RSI) 32.13 48.51
Support Level $51.15 $31.60
Resistance Level $70.98 $35.75
Average True Range (ATR) 2.24 2.35
MACD -1.28 -0.28
Stochastic Oscillator 7.17 19.25

Price Performance

Historical Comparison
PHIN
STOK

About PHIN PHINIA Inc.

Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, the company generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: